Pharma & Bio
Lifestyle
Dicigen’s Next-Generation Breast Cancer Prognosis Prediction Kit Passes New Medical Technology Evaluation… Expected to Generate Over 10 Billion Next Year
D-Cigen, a company specializing in precision medicine and genetic diagnostics, is set to begin full-scale distribution in South Korea of “OncoFREE,” its proprietary next-generation sequencing (NGS)-ba…
- 2026-10-23 07:06:03
- YU JIN-HEE
Technology
Jugaije, Establishing a Korean Subsidiary: Partnership with JW on Hemlibra Continues... Will It Develop New Drugs Independently?
(Graphic: ChatGPT)
Japanese pharmaceutical company Chugai Pharmaceutical, which is establishing a subsidiary in South Korea, has expanded its options for operating its domestic business. While con…
- 2026-10-23 07:06:02
- Minji Son
Lifestyle
Following ADC, ‘XDC’ Draws Attention from Big Pharma… Aptabio Therapeutics Inc. Pursues ‘Platform Deal’
Aptabio Therapeutics Inc.(293780)is exploring opportunities to export its platform technology, led by the aptamer-based drug delivery platform “Apta-DC.” Apta-DC is a technology designed to overcome d…
- 2026-10-23 00:41:02
- Kim Jinsoo
Technology
Kim Dong-min, CEO of JLK, Inc.: "In Discussions for a Contract with a Japanese Medical University… Expecting a Major Contract Through Itochu Corporation"
“We are in discussions regarding a contract to use our solution in nationwide clinical trials in Japan. If a major hospital adopts it, it could quickly spread to affiliated regional hospitals.”Kim Don…
- 2026-10-22 10:02:02
- Kim Seung-kwon
Technology
KH Green, a 'Key Pillar of Cha Won-tae’s Succession Plan': Why Were All Its Shares in Chabiotech Co.,Ltd. Pledged as Collateral? [Chabiotech Co.,Ltd. Deep Dive ②]
The financial investor (FI) risk associated with Cha Healthcare has spread beyond Chabiotech Co.,Ltd. to KH Green, a key pillar of Vice Chairman Cha Won-tae’s control. KH Green’s entire stake in Chabi…
- 2026-10-22 07:01:03
- KIM SAE-MI
Technology
[Exclusive] Peptron, Inc. Terminates 'PT302' Technology Transfer Agreement with Yuhan Corporation After 15 Years… Why?
Peptron, Inc.(087010)has terminated the technology transfer agreement for “PT302,” a glucagon-like peptide-1 (GLP-1) class diabetes treatment, which it had maintained with Yuhan(000100)for 15 years. P…
- 2026-10-22 06:51:02
- KIM SAE-MI
Business·Industry
iNtRON Biotechnology, Inc. Focuses on MTAs… Curiox Falls on Concerns Over Potential Technology Leaks and Disputes [Bio Spotlight]
On the 20th, in the pharmaceutical and biotech sector, iNtRON Biotechnology, Inc.(048530)drew investors’ attention after signing a Material Transfer Agreement (MTA) for subcutaneous (SC) injection tec…
- 2026-10-22 06:42:02
- Kim Jinsoo
Lifestyle
Oh Se-mun, CEO of SG BioScience: “We Will Usher in an Era of 200 Billion Won in Sales with New Products”
“Once our independently developed eco-friendly quantum dot (QD) diagnostic platform gains a foothold in the global market, we can achieve sales of over 80 billion won from this single product line alo…
- 2026-10-22 06:31:02
- YU JIN-HEE
Technology
G2GBIO Hits Limit-Up on China Partnership; Inventera Gains on U.S. Clinical Trial Approval [K-Bio Pulse]
On Oct. 19, South Korean pharmaceutical and biotech stocks rose across the board, buoyed by company-specific developments and easing concerns over potential production disruptions. Samsung Biologics s…
- 2026-10-21 08:02:02
- Minji Son
Technology
G2GBIO, Inc. Partners with Chinese Pharmaceutical Company, Shares Rise… Inventera Inc. Gets Green Light for U.S. Clinical Trials [Bio Spotlight]
On the 19th, domestic pharmaceutical and biotech stocks showed an overall upward trend, driven by positive developments at individual companies, such as business progress and easing concerns over prod…
- 2026-10-21 08:01:02
- Minji Son
PHARM EDAILY
Shorts